<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944268</url>
  </required_header>
  <id_info>
    <org_study_id>E01-AT-CAL-03-08</org_study_id>
    <nct_id>NCT00944268</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability Study to Treat Mild and Moderate Anxiety</brief_title>
  <acronym>E01ATCAL0308</acronym>
  <official_title>Clinical Study Phase III, Multicenter, Prospective, Open to Evaluate the Efficacy and Tolerability of the Combination Use of Passiflora Incarnata L, Crataegus Oxyacantha and Salix Alba L in Mild and Moderate Anxiety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ativus Farmaceutica Ltda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ativus Farmaceutica Ltda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and tolerability of the combination use of Passiflora incarnata L,
      Crataegus oxyacantha and Salix alba L in mild and moderate anxiety.

      Clinical study phase III, multicenter, prospective, open.

      Patients will be included in sufficient quantity to achieve the minimum number of 124
      evaluable patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">January 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Scales</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation by adverse events relate.</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Anxiety</condition>
  <condition>Efficacy</condition>
  <condition>Tolerability</condition>
  <arm_group>
    <arm_group_label>Liquid and solid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Passiflora, Crataegus e Salix</intervention_name>
    <description>Comparison of different pharmaceutics forms of drug</description>
    <arm_group_label>Liquid and solid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who achieve scores between 18 and 29 points in the Hamilton Scale for
             Anxiety;

          -  Individuals of any ethnic group male and female, aged above 18 years;

          -  Consent of the subject of research (a consent form signed).

        Exclusion Criteria:

          -  Patients with known hypersensitivity to any components of the formula;

          -  Pregnant women and nursing mothers;

          -  Patients with endogenous depression, schizophrenia, suicidal tendency;

          -  Patients with heart disease unabated, unabated kidney, liver and lung unabated
             unabated, at the discretion of the investigator;

          -  Addiction to drugs, including alcohol, at the discretion of the investigator;

          -  Patients who are using any medication that could interfere with the effect of the drug
             under study;

          -  Impossibility of compliance to the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elie Fiss</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculdade de Medicina do ABC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dagoberto Brandão</last_name>
    <phone>55 11 36733763</phone>
    <email>dagoberto@phcbrasil.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09060650</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elie Fiss</last_name>
      <phone>55 1149935469</phone>
      <email>eliefiss@uol.com.br</email>
    </contact>
    <investigator>
      <last_name>Elie Fiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>July 23, 2009</last_update_submitted>
  <last_update_submitted_qc>July 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Olinto Mascarenhas Marques</name_title>
    <organization>ATIVUS FARMACÊUTICA LTDA</organization>
  </responsible_party>
  <keyword>Passiflora, Crataegus and Salix</keyword>
  <keyword>Mild and Moderate anxiety</keyword>
  <keyword>Tablet</keyword>
  <keyword>To evaluate the efficacy and tolerability of the combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

